Resources Investment Advisors Inc. lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 93.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,793 shares of the company’s stock after selling 43,334 shares during the period. Resources Investment Advisors Inc.’s holdings in Novo Nordisk A/S were worth $138,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. BB&T Securities LLC lifted its stake in Novo Nordisk A/S by 8.4% in the first quarter. BB&T Securities LLC now owns 271,247 shares of the company’s stock worth $13,358,000 after purchasing an additional 21,016 shares during the last quarter. Carillon Tower Advisers Inc. bought a new stake in Novo Nordisk A/S in the first quarter worth about $15,194,000. Institutional & Family Asset Management LLC bought a new stake in Novo Nordisk A/S in the first quarter worth about $156,000. Loomis Sayles & Co. L P lifted its stake in Novo Nordisk A/S by 6.4% in the first quarter. Loomis Sayles & Co. L P now owns 22,025,113 shares of the company’s stock worth $1,084,737,000 after purchasing an additional 1,323,857 shares during the last quarter. Finally, Polen Capital Management LLC lifted its stake in Novo Nordisk A/S by 19.8% in the first quarter. Polen Capital Management LLC now owns 22,433 shares of the company’s stock worth $1,105,000 after purchasing an additional 3,714 shares during the last quarter. Institutional investors own 6.70% of the company’s stock.
Shares of Novo Nordisk A/S opened at $46.85 on Thursday, according to Marketbeat. The stock has a market capitalization of $115.77 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 2.48 and a beta of 0.69. Novo Nordisk A/S has a 1 year low of $41.03 and a 1 year high of $58.37.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, May 2nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.04. Novo Nordisk A/S had a net margin of 35.21% and a return on equity of 82.78%. The business had revenue of $4.44 billion during the quarter, compared to the consensus estimate of $4.49 billion. equities analysts forecast that Novo Nordisk A/S will post 2.57 EPS for the current year.
Separately, Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $64.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.